BTIG analyst Ryan Zimmerman reiterated a Buy rating on Organogenesis Holdings Inc (ORGO – Research Report) yesterday and set a price target of $12. The company’s shares closed last Monday at $3.81, close to its 52-week low of $3.80.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 19.2% and a 58.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
Currently, the analyst consensus on Organogenesis Holdings Inc is a Moderate Buy with an average price target of $12.
The company has a one-year high of $310.90 and a one-year low of $3.80. Currently, Organogenesis Holdings Inc has an average volume of 51.91K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.